Moulder Leon O Jr.

Insider Reports History

Reporting-owner location: Waltham, MA
Latest reporting-owner signature: /s/ Bruce Blefeld, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Moulder Leon O Jr.

Form 4 holding Director

Dianthus Therapeutics, Inc. /DE/

Security class: Common Stock
Shares / value: 1,436,745
Estimated value: $17,240,940
Report date: 22 Jan 2024
Price: $12.00
Ownership: Indirect

Form 4 holding Chief Executive Officer, Director

Zenas BioPharma, Inc.

Security class: Common Stock
Shares / value: 423,155
Estimated value: $8,272,680
Report date: 18 May 2026
Price: $19.55
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Zenas BioPharma, Inc.

Security class: Common Stock
Shares / value: 96,928
Estimated value: $1,636,144
Report date: 18 May 2026
Price: $16.88
Ownership: Indirect

Form 4 holding Director

Zai Lab Ltd

Security class: American Depositary Shares
Shares / value: 94,973
Estimated value: $1,317,860
Report date: 17 Jun 2026
Price: $21.33
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Zenas BioPharma, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 500,000
Estimated value
Report date: 15 Jun 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

TREVENA INC

Security class: Stock Option (Right to Buy)
Shares / value: 13,700
Estimated value
Report date: 15 Jun 2023
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Dianthus Therapeutics, Inc. /DE/

Security class: Stock Option (Right to Buy)
Shares / value: 11,000
Estimated value
Report date: 23 May 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Moulder Leon O Jr.

4 ZLAB

Zai Lab Ltd

Report period: 17 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Jun 2026, 16:08
Role: Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 15 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jun 2026, 18:02
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 18 May 2026
Transactions: 1
Transaction value: +$1,012,800
Accepted by SEC: 18 May 2026, 21:12
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 28 Apr 2026
Transactions: 2
Transaction value: +$1,067,200
Accepted by SEC: 29 Apr 2026, 19:21
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 30 Mar 2026
Transactions: 2
Transaction value: +$1,021,140
Accepted by SEC: 31 Mar 2026, 20:14
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 02 Feb 2026
Transactions: 1
Transaction value: +$1,023,720
Accepted by SEC: 03 Feb 2026, 16:30
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 07 Jan 2026
Transactions: 3
Transaction value: +$1,639,000
Accepted by SEC: 09 Jan 2026, 21:42
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 07 Oct 2025
Transactions: 1
Transaction value: +$769,949
Accepted by SEC: 09 Oct 2025, 17:24
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZLAB

Zai Lab Ltd

Report period: 18 Jun 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 23 Jun 2025, 16:11
Role: Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 10 Jun 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 12 Jun 2025, 16:30
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 18 Feb 2025
Transactions: 1
Transaction value: +$166,750
Accepted by SEC: 19 Feb 2025, 16:01
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 03 Dec 2024
Transactions: 2
Transaction value: +$718,100
Accepted by SEC: 04 Dec 2024, 21:03
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 18 Nov 2024
Transactions: 2
Transaction value: +$148,925
Accepted by SEC: 20 Nov 2024, 17:20
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZBIO

Zenas BioPharma, Inc.

Report period: 18 Sep 2024
Transactions: 4
Transaction value: +$360,820
Accepted by SEC: 20 Sep 2024, 18:34
Role: Chief Executive Officer, Director
Next action: Open filing details

4/A ZBIO

Zenas BioPharma, Inc.

Report period: 12 Sep 2024
Transactions: 9
Transaction value: $0
Accepted by SEC: 17 Sep 2024, 20:54
Role: Chief Executive Officer, Director
Next action: Open filing details

3 ZBIO

Zenas BioPharma, Inc.

Report period: 12 Sep 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 12 Sep 2024, 21:33
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ZLAB

Zai Lab Ltd

Report period: 18 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Jun 2024, 17:00
Role: Director
Next action: Open filing details

4 DNTH

Dianthus Therapeutics, Inc. /DE/

Report period: 23 May 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 28 May 2024, 19:58
Role: Director
Next action: Open filing details

4 DNTH

Dianthus Therapeutics, Inc. /DE/

Report period: 22 Jan 2024
Transactions: 1
Transaction value: +$2,000,004
Accepted by SEC: 24 Jan 2024, 19:04
Role: Director
Next action: Open filing details

4 DNTH

Dianthus Therapeutics, Inc. /DE/

Report period: 11 Sep 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Sep 2023, 21:13
Role: Director
Next action: Open filing details

3 DNTH

Dianthus Therapeutics, Inc. /DE/

Report period: 11 Sep 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 13 Sep 2023, 20:46
Role: Director
Next action: Open filing details

4 ZLAB

Zai Lab Ltd

Report period: 29 Jun 2023
Transactions: 1
Transaction value: +$499,984
Accepted by SEC: 30 Jun 2023, 16:06
Role: Director
Next action: Open filing details

4 TRVN

TREVENA INC

Report period: 15 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Jun 2023, 16:36
Role: Director
Next action: Open filing details

4 TRVN

TREVENA INC

Report period: 09 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Jun 2022, 17:27
Role: Director
Next action: Open filing details

4 ZLAB

Zai Lab Ltd

Report period: 03 Jan 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Jan 2022, 20:14
Role: Director
Next action: Open filing details

4 TRVN

TREVENA INC

Report period: 28 May 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Jun 2021, 17:01
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .